Problems and limitations of cardiac transplantation A. Rukosujew, S. Klotz, H.H. Scheld Westfälische Willhelms -Universität Münster Klinik und Poliklinik.

Slides:



Advertisements
Similar presentations
HEART TRANSPLANTATION
Advertisements

Anti-Inflammatory & Immunosuppressive Drugs 2
International Progress In Heart Transplantation and The “Vienna Factor” Mandeep R. Mehra, MD President, International Society For Heart and Lung Transplantation.
Compassionate Allowances Outreach Hearing on Cardiovascular Disease and Multiple Organ Transplants Clive O. Callender, M.D., FACS November 9, 2010 Clive.
Everolimus plus Reduced-Exposure CsA is as Effi cacious as Mycophenolic Acid plus Standard-Exposure CsA Reference: Silva Jr HT, Cibrik D, Johnston T, et.
™ Principles of Transplantation Karl D. Pilson MD Suresh Agarwal MD, FACS, Boston University Medical School Boston Medical Center Boston, MA.
Prolonged Diabetes Reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates Hering et al, Nature.
1. 2  Background (K)  Induction agents (M)  Overview of Immunosuppressants (K) › Calcineurin inhibitors › Antiproliferative agents › Proliferation.
Conversion from CNI to sirolimus Byung Chul Shin Division of Nephrology Chosun University Hospital, Gwangju.
30-Year Retrospective on Organ Transplant Immunosuppression in the Era of Calcineurin Inhibitors Herwig-Ulf Meier-Kriesche, MD Professor of Medicine Department.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 69 Immunosuppressants.
Charcot neuroarthropathy after Simultaneous Pancreas Kidney transplantation: risk factors and evolution of prevalence over 20 years. Prof. Dr. GA Matricali.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
CHAPTER 3 HEART AND LUNG TRANSPLANTATION Editors: Mr Mohamed Ezani Md. Taib Dato’ Dr David Chew Soon Ping Dr Ashari Yunus Expert Panel: Mr Mohamed Ezani.
Causes of Graft Loss over 10 Years in CsA-Treated Patients Recurrent disease 6% Vascular 8% PNF 5% Acute Rejection 11% Other 3% CAN 40% Death 27% Marcén.
Kidney Transplantation An Overview
CNI toxicity and mTOR inhibitors or the old switcheroo.
New Developments in the Management of Kidney Transplant Patients
Principles of Transplant Surgery Ruth Mitchell, BA, BSc, BMBS Neurosurgical Resident Royal Melbourne Hospital Thursday, 25 th March 2010.
Renal (Kidney) Transplantation Kidney Transplant Inserting a kidney of another live or dead person into a person. The donor kidney is typically placed.
Kim Dosch, PT Tina Fields, PT, CCS 06/20/2013
1 Current Status and Future Challenges in Heart Transplantation Mark L. Barr, M.D. Associate Professor of Cardiothoracic Surgery Co-Director, Cardiothoracic.
BWGHF Liège Heart transplantation 2008.
Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients
HEART TRANSPLANTATION Pediatric Recipients JHLT Oct; 32(10):
Transplantation Surgery M K Alam MS, FRCS. ILOs At the end of this presentation students should be able to: Define terminology used in transplantation.
Experience with Calcineurin Inhibitor-Free Immunosuppression in Kidney Transplantation with Marginal Donors Oppenheimer F, Saval N, Gutierrez A, Cam pistol.
Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.
Immunosuppressant Drugs
Transplantation - Immunosuppression A Case-based Approach January 20, 2009 Paul D. Greig, MD, FRCS(C) Professor of Surgery University of Toronto.
Update on Pediatric Cardiac Transplantation Dr Jameel Al-ata Consultant & Assistant Professor of Pediatrics & Pediatric Cardiology Taif April 2007.
Mycophenolate mofetil A suppression tale ד " ר יוסי רימר.
TRANSPLANTATION CHAPTER 8 ANZDATA Registry Annual Report 2013.
Table 5.1.1: Stock and Flow of Renal Transplantation, Year New transplant patients
CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.
Immunology of transplantation. Types of transplantation Autotransplantation –within one organism Allotransplantation- between one species Xenotransplantation-
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
© 2014 Direct One Communications, Inc. All rights reserved. 1 How to Maximize Outcomes and Minimize Graft Failure Thin Thin Maw, MBBS Washington University.
Advanced Therapies Lee R. Goldberg, MD, MPH Medical Director, Heart Failure and Cardiac Transplant Program University of Pennsylvania.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 45 Immunosuppressant Drugs.
Table 3.1.1: Stock and Flow of Heart Transplantation, Year New transplant patients Deaths
RAD Immunosuppression in Heart Transplant Recipients Duke Heart Failure Research Pager:
Table 3.1.1: Stock and Flow of Heart Transplantation, Year New transplant patients Deaths
Immunopharmacology 8 March :42 AM.
IMMUNOSUPPRESSANT THERAPY DR FATAI OLUYADI USMLEINCLINED.COM 1.
Thymoglobulin: An Overview of Its Performance in Clinical Trials as an Agent for the Induction Therapy Reference: Osama Gaber A, Knight RJ, Patel S, et.
Kidney Transplantation. Best treatment of chronic renal failure.
History of Kidney Transplantation
CM-1 Current Status of Lung Transplantation Jeff Golden, MD Professor of Clinical Medicine and Surgery Medical Director, Lung Transplantation University.
Epstein-Barr virus re-activation in post-kidney transplant period: risk factors and specific immune- responses Erica Franceschini.
Graft Dysfunction after Heart Transplantation
Lupus Nephritis Treatment
Table 3.1.1a: Stock and Flow of Heart Transplantation,
Immuno-pharmacology 4th Class Dr Sherzad Kh. RASHID
Number of Grafts Performed by Country
KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients 순천향대학교 서울병원 신장내과 R2 김윤석.
Tissue and Organ Transplantation
Liver Transplantation: 50 years
Updates in Transplant Medication and Technology
Updates in Transplant Medication
Transplantation Immunology
Review of Heart-Lung Transplantation at Stanford
ANZDATA Registry Annual Report 2013
Renal replacement therapy
Transplantation Immunology
Overcoming Barriers to Long-Term Graft Survival
Cardiac Transplantation in Pediatric Patients: Fifteen-Year Experience of a Single Center  Jan Groetzner, MD, Bruno Reichart, MD, Ulrich Roemer, MD, Stefanie.
Kidney Transplantation
Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.
Assistant professor of Hepatology Alexandria University
Presentation transcript:

Problems and limitations of cardiac transplantation A. Rukosujew, S. Klotz, H.H. Scheld Westfälische Willhelms -Universität Münster Klinik und Poliklinik für Thorax-, Herz- und Gefäßchirurgie

Cancer End-stage Heart Failure Prognosis* Problems and limitations of cardiac transplantation Survival *Harrison‘s Principles of Internal Medicine (14th Edition) 1998

Problems and limitations of cardiac transplantation Progressive improvement in survival* *Hunt SA, Haddad F JACC 2008;52: In terms of days or weeks over 3 decades 10 In excess of 10 years

Eurotransplant Problems and limitations of cardiac transplantation Tolerance of ischemia 4 h Transport time< 2,5 h Explant radius > 1000 km

Problems and limitations of cardiac transplantation Organ donation in Europa/Germany

International organ donation Problems and limitations of cardiac transplantation

Top 10 Problems and limitations of cardiac transplantation : 377 transplantations in Germany

Donor shortage I Problems and limitations of cardiac transplantation 29%

Donor shortage II Problems and limitations of cardiac transplantation Eurotransplant waiting list

Biatrial technique Biatrial technique* Problems and limitations of cardiac transplantation * Lower RR, Shumway NE Surg Forum 1960;11:18-19

Bicaval technique* Problems and limitations of cardiac transplantation * Sievers HH et al Thorac Cardiovasc Surg 1991;39:70-72

Total orthotopic technique* Problems and limitations of cardiac transplantation Total orthotopic HTX by W.P. Demichow in 1951 * Dreyfus G et al Ann Thorac Surg 1991;52:1181-4

Survival after HTX* Problems and limitations of cardiac transplantation HTX (UKM) 396 *1990 – oHTX in Muenster

After HTX I Problems and limitations of cardiac transplantation Rejection Infection Corticosteriods Cyclosporine Tacrolimus Azathioprine Mycophenolic acid Sirolimus Hypertension Hyperlipidemia Renal failure Osteoporosis Diabetes mellitus Malignant tumours Graft vasculopathy Graft vasculopathy host-graft adaptation

After HTX II Problems and limitations of cardiac transplantation

Day-to-day problems Problems and limitations of cardiac transplantation Crowded gathering Plants Domestic animals Transport facilities

Immunosuppression I Problems and limitations of cardiac transplantation Goal: to prevent or treat rejection minimizing the risk of infection or cancer 6-Mercaptopurin Azathioprine Ciclosporine OKT3 Tacrolimus Mycophenolate mofetil (MMF) Basiliximab/daclizumab Sirolimus Na-Mycophenolate (EC-MPS) Everolimus

Immunosuppressive agents Problems and limitations of cardiac transplantation Calcineurin inhibitorsCyclosporine Tacrolimus Purine synthesis inhibitorsMycophenolate mofetil Azathioprine Proliferation signal inhibitorsSirolimus Everolimus CorticosteroidsPrednisone / Prednisolone Polyclonal antibodiesAntithymocyte globulin Antilymphocyte globulin Monoclonal antibodiesRituximab Daclizumab / Basiliximab

Immunosuppression II Problems and limitations of cardiac transplantation Dual therapy  CsA + Steroids  Tac + Steroids  CsA + polyklonal antibodies Triple therapy  CsA + Aza + Steroids  CsA + EC-MPS + Steroids  CsA/Tac + MMF + Steroids  Basiliximab + CsA + Steroids  CsA + Everolimus + Steroids Quadruple therapy  CsA + Aza + Ster. + OKT3  CsA + Sirolimus + MMF + Ster.  CsA + Everolimus + MMF + Ster. 200 There are more then 200 maintenance regimens & methods for rejection managing

Immunosuppression III Problems and limitations of cardiac transplantation

Quality of life I Problems and limitations of cardiac transplantation

Quality of life Problems and limitations of cardiac transplantation

Summary Heart transplantation not be planned (waiting time) donor shortage hypothermic organ preservation (reperfusion injury) side effects of immunsuppression (infection, tumour) better quality and length of life improved monitoring of rejection development of better immunosuppresive regimens